CC BY 4.0 · Glob Med Genet 2022; 09(02): 060-062
Genomic and Immunologic Markers of Intrinsic Resistance to Pembrolizumab Monotherapy
in Microsatellite Instability-High Gastric Cancer: Observations from a Prospective
Phase II Study
Haibo Qiu
1
Department of Gastric Surgery, Sun Yat-sen University Cancer Center, Guangzhou, People's
Republic of China
› Author Affiliations
References
1
Siegel RL,
Miller KD,
Jemal A.
Cancer statistics, 2020. CA Cancer J Clin 2020; 70 (01) 7-30 2
Cao M,
Li H,
Sun D,
Chen W.
Cancer burden of major cancers in China: a need for sustainable actions. Cancer Commun
(Lond) 2020; 40 (05) 205-210 3
Gao K,
Wu J.
National trend of gastric cancer mortality in China (2003-2015): a population-based
study. Cancer Commun (Lond) 2019; 39 (01) 24 4
Feng RM,
Zong YN,
Cao SM,
Xu RH.
Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?.
Cancer Commun (Lond) 2019; 39 (01) 22 5
Kim JY,
Shin NR,
Kim A.
et al.
Microsatellite instability status in gastric cancer: a reappraisal of its clinical
significance and relationship with mucin phenotypes. Korean J Pathol 2013; 47 (01)
28-35 6
Folprecht G.
Tumor mutational burden as a new biomarker for PD-1 antibody treatment in gastric
cancer. Cancer Commun (Lond) 2019; 39 (01) 74 7
Chang L,
Chang M,
Chang HM,
Chang F.
Microsatellite instability: a predictive biomarker for cancer immunotherapy. Appl
Immunohistochem Mol Morphol 2018; 26 (02) e15-e21 8
Chao J,
Fuchs CS,
Shitara K.
et al.
Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high
gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061,
and KEYNOTE-062 clinical trials. JAMA Oncol 2021; 7 (06) 895-902 9
Fuchs CS,
Doi T,
Jang RW.
et al.
Safety and efficacy of pembrolizumab monotherapy in patients with previously treated
advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059
trial. JAMA Oncol 2018; 4 (05) e180013 10
Shitara K,
Özgüroğlu M,
Bang YJ.
et al;
KEYNOTE-061 investigators.
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal
junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Lancet 2018; 392 (10142): 123-133 11
Marabelle A,
Fakih M,
Lopez J.
et al.
Association of tumour mutational burden with outcomes in patients with advanced solid
tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort,
open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020; 21 (10) 1353-1365 12
Kwon M,
An M,
Klempner SJ.
et al.
Determinants of response and intrinsic resistance to PD-1 blockade in microsatellite
instability-high gastric cancer. Cancer Discov 2021; 11 (09) 2168-2185 13
Mandal R,
Samstein RM,
Lee KW.
et al.
Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy
response. Science 2019; 364 (6439): 485-491 14
Schrock AB,
Ouyang C,
Sandhu J.
et al.
Tumor mutational burden is predictive of response to immune checkpoint inhibitors
in MSI-high metastatic colorectal cancer. Ann Oncol 2019; 30 (07) 1096-1103 15
Qian J,
Nie W,
Lu J.
et al.
Racial differences in characteristics and prognoses between Asian and white patients
with nonsmall cell lung cancer receiving atezolizumab: an ancillary analysis of the
POPLAR and OAK studies. Int J Cancer 2020; 146 (11) 3124-3133
